​

Funding Round

Series B - Lassen Therapeutics

Series B - Lassen Therapeutics

Investment Firm

Overview

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Announced Date

Dec 19, 2023

Closed on Date

Dec 19, 2023

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Longitude Capital

Longitude Capital

Longitude Capital is a debt and early_stage_venture and late_stage_venture and private_equity and venture firm.

Frazier Life Sciences

Frazier Life Sciences

Frazier Life Sciences is a early_stage_venture and late_stage_venture and post_ipo and seed firm.

Participant Investors

4

Investor Name
Participant InvestorFrazier Life Sciences
Participant InvestorCatalio Capital Management
Participant InvestorAlta Partners
Participant InvestorLongitude Capital

Round Details and Background

Lassen Therapeutics raised $85000000 on 2023-12-19 in Series B

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 17, 2020
Series A - Lassen Therapeutics
3-31.0M
Dec 19, 2023
Series B - Lassen Therapeutics
6-85.0M

Recent Activity

There is no recent news or activity for this profile.